Medibio Announces Regarding Notice Received Under Section 249D Of The Corporations Act

On 1 October 2018, the Medibio Limited (ASX: MEB) announced that on 28 September it received a notice under Section 249D of the Corporations Act 2001 (Section 249D Notice) requesting the Company call and arrange to hold a meeting of the members of the Company. The Section 249D Notice seeks the appointment of Mr. Benjamin Richardson, Ms. Peta Slocombe, and Mr. Elias Khouri as Directors of the Company and the removal of Mr. Chris Indermaur and Mr. Andrew Maxwell as Directors of the Company. On 5 October 2018, the company released its Investor presentation following which the share price of the company decreased by 1.515%.  [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

In FY 2018, the company earned a revenue of $2.6 million which was $3.16 million in FY 2017. The Company’s loss increased from $9.78 million in FY 2017 to $16.3 million in FY2018. Resultantly, the basic and diluted loss per share increased from 7.443 cents in FY 2017 to 8.805 cents in FY 2018. Net cash used in operating activities increased from $5.42 million in FY 2017 to $12.27 million in FY 2018. The cash at bank of the company increased from $5.01 million in FY 2017 to $6.12 million in FY 2018. The Company’s ability to continue as a going concern is dependent upon the generation of cash from operations, the sufficiency of current cash reserves to meet existing obligations, research, and development tax incentives, the ability to reschedule planned research and development activity and raising of further equity and receipt of grant funding. The company issued 38,736,640 shares, raising $13,945,190 before issue costs on 20 October 2017 and on 11 October 2017, a total of 10,000,000 options were issued with an expiry of 11 October 2022 and exercise price of 45 cents.

In the past three months, the share price of the company decreased by 56% to $0.066 as on 4 October 2018. The MEB’s share traded at $0.065 with the market capitalization of $13.37 million as on 5 October 2018 (AEST 4:00 PM).

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report